Repeated low-level red-light therapy for improving asthenopic symptoms and accommodation in presbyopia.

Ann MedApr 28, 2026 (epub)
Clinical ResearchOphthalmologyOpen access

Fan Song, Ziwei Zhao, Jian Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of repeated low-level red light (RLRL) therapy in alleviating asthenopia and enhancing accommodation in 64 adults with presbyopia. After one month, RLRL therapy resulted in a significant improvement in the Computer Vision Syndrome Questionnaire (CVS-Q) score, with an adjusted mean difference of -1.75 points compared to sham treatment.

Key findings

  • RLRL therapy improved CVS-Q score by an adjusted mean difference of -1.75 points compared to sham.
  • Accommodative amplitude increased by 1.09 D in the RLRL group.
  • NAVQ score improved by -8.07 points in the RLRL group.
  • No treatment-related adverse events were reported.

Why it matters

The findings suggest that RLRL therapy may provide a non-invasive option for managing asthenopia and improving visual function in presbyopic patients, potentially enhancing their quality of life.

Source

PubMed · PMID 42046494Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.